Objectives: To determine whether blood flow rate influences circuit life in continuous renal replacement therapy. Design: Prospective randomized controlled trial. Setting: Single center tertiary level ICU. Patients: Critically ill adults requiring continuous renal replacement therapy. Interventions: Patients were randomized to receive one of two blood flow rates: 150 or 250 mL/min. Measurements and Main Results: The primary outcome was circuit life measured in hours. Circuit and patient data were collected until each circuit clotted or was ceased electively for nonclotting reasons. Data for clotted circuits are presented as median (interquartile range) and compared using the Mann-Whitney U test. Survival probability for clotted circuits was compared using logrank test. Circuit clotting data were analyzed for repeated events using hazards ratio. One hundred patients were randomized with 96 completing the study (150 mL/min, n = 49; 250 mL/min, n = 47) using 462 circuits (245 run at 150 mL/min and 217 run at 250 mL/min). Median circuit life for first circuit (clotted) was similar for both groups (150 mL/min: 9.1 hr [5.5-26 hr] vs 10 hr [4.2-17 hr]; p = 0.37). Continuous renal replacement therapy using blood flow rate set at 250 mL/min was not more likely to cause clotting compared with 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68). Gender, body mass index, weight, vascular access type, length, site, and mode of continuous renal replacement therapy or international normalized ratio had no effect on clotting risk. Continuous renal replacement therapy without anticoagulation was more likely to cause clotting compared with use of heparin strategies (hazards ratio, 1.62; p = 0.003). Longer activated partial thromboplastin time (hazards ratio, 0.98; p = 0.002) and decreased platelet count (hazards ratio, 1.19; p = 0.03) were associated with a reduced likelihood of circuit clotting. Conclusions: There was no difference in circuit life whether using blood flow rates of 250 or 150 mL/min during continuous renal replacement therapy. (Crit Care Med 2017; 45:e1018-e1025) 
The impact of BFR on membrane clotting rate is potentially important and has not been examined in controlled studies. Despite suggestions to increase BFRs in the EC (11, 12) , there remains great variability in the prescription of this setting worldwide. Although a recent survey of Australian and New Zealand ICUs indicated a BFR of 150-200 mL/min was the dominant setting, a faster rate of 200-250 mL/min was also commonplace in ICUs surveyed (13) . Observational studies and recent worldwide practice surveys of CRRT also demonstrate great variability in practice from 80 mL/min (12) to 350 mL/min (14) (15) (16) . Although BFR may be an important determinant of circuit life in CRRT, the most suitable speed to reduce clotting and optimize membrane life has not been identified. To address this question, we conducted a prospective randomized controlled trial (RCT). We tested the hypothesis that a faster BFR (250 mL/min) would be superior to a slower BFR (150 mL/min) in maintaining circuit patency in CRRT.
MATERIALS AND METHODS

Trial Design and Setting
This study was a prospective, parallel group RCT conducted in a 24-bed, adult, tertiary intensive care in Melbourne, Victoria, Australia. The study was registered at the Australian New Zealand Clinical Trials Registry (ACTRN: 12615001353583) and approved by Austin Health Human Research Ethics Committee (HREC project No. H2012/04772). Written informed consent was obtained from the patient or their next of kin prior to, or soon after enrollment.
Eligibility Criteria
Critically ill patients in ICU were eligible for the study if they fulfilled three criteria: 1) greater than or equal to 18 years old, 2) AKI (Risk, Injury, Failure [F] , Loss, and End-stage kidney disease classification F) (16) requiring CRRT, and 3) vascular access was via the femoral vein for standardization. Patients were considered ineligible for the study if they fulfilled any of the following exclusion criteria: 1) required citrate anticoagulation (citrate protocol requires set BFR of 150 mL/min) and 2) expected stay in the ICU was less than 24 hours.
Interventions
The study compared two BFR settings on circuit life in CRRT. The intervention was a set BFR of 250 mL/min, and the control was a set BFR of 150 mL/min. CRRT was performed using continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) modality. Vascular access was via either Niagara 13.5F catheter (24 cm) (Bard, Murray Hill, NJ) or Gamcath Dolphin Protect 13.0F catheter (25 cm) (Gambro, Hechingen, Germany) dual lumen catheters. Treatment modality and choice of vascular access were at the discretion of the treating physician. Prismaflex with AN69ST (ST100) 1.0 m 2 membrane (Gambro Nephral TM, Lund, Sweden) or Infomed HF 440 with DF 140 Polyethersulfone 1.4 m 2 membrane (Infomed, Geneva, Switzerland) was used for all treatments. Bicarbonate buffered replacement and dialysis fluid (Baxter, Castlebar, County Mayo, Ireland) was used. In CVVH, replacement fluid was delivered into the EC before and after the filter (pre and postdilution), with a ratio of 50% predilution and 50% postdilution. Dose in CVVH was standardized at 2,000 mL/hr. In CVVHDF, the replacement fluid was all delivered postdilution. Dose in CVVHDF was standardized at 1,000 mL/hr replacement and 1,000 mL/hr dialyzate.
Anticoagulation was provided according to a predefined ICU protocol and mandates no anticoagulation in patients at risk of bleeding from a coagulopathy or thrombocytopenia. Options for anticoagulation when used included regional heparinization with unfractionated heparin (UFH) (1,000 IU/hr) delivered prefilter and protamine (10 mg/hr) delivered in the return limb of the EC for reversal of heparin. UFH was used alone and delivered prefilter at 5-10 IU/kg/hr. CRRT was prescribed by the treating intensivist and delivered by ICU nurses. The decision to start or stop CRRT, and determining the reason for stopping, was done by ICU doctors and nurses, respectively, as is usual protocol for the ICU. 
Data Collection
Outcomes
The primary outcome was circuit life (measured in hours) and recorded as clotted when 1) transmembrane pressure across the circuit exceeded 300 mm Hg, 2) prefilter pressure greater than 200 mm Hg, 3) visible clot obstructing flow through the circuit, and 4) the blood pump was unable to rotate due to clot obstruction in the membrane or for "elective" reasons, for example, CT, MRI, surgical intervention, or cessation prior to clotting for native renal assessment.
Sample Size
Without supportive data to inform a power calculation for this study, 100 patients were chosen to ensure a sample that was sufficient to reflect usual ICU patient characteristics and allow recruitment completion in 1 year. Patients stayed in the BFR treatment group allocated at randomization. The treating physician prescribed the CRRT modality for each patient (CVVH or CVVHDF) which was maintained/retained for all subsequent treatments. All circuits used for these patients were included and analyzed accordingly.
Randomization
Patients were screened and entered the study by ICU clinical staff. Patients were randomly assigned with stratification for mode (CVVH or CVVHDF). Once the treating physician prescribed CRRT and the mode of therapy, patients were randomized using a web-based central randomization service. A variable block randomization with parallel allocation was used to allocate to each study group (150 vs 250 mL/min).
Statistical Methods
The primary outcome (circuit life) was analyzed in a two-step process. First analysis: this excluded all electively removed or nonclotted circuits from the data. The distribution of data for all circuits meeting the defined clotting criteria was then assessed. As expected, study variables were not normally distributed and nonparametric statistics were used with circuit life reported as median and interquartile range (IQR). Circuit life for the two groups (150 vs 250 mL/min) was compared using Mann-Whitney U test. Analysis of the two groups was then assessed for survival probability and presented graphically using Kaplan-Meier survival plots. A log-rank test was used to compare circuit life between the two groups. This analysis was not adjusted for any confounding variables.
Second analysis included all circuits (clotted and those electively removed). Circuit life was analyzed using repeated events survival analysis (7, 17) . A proportional hazard conditional frailty model (17) (an extension of Cox regression) was used to test for within patient dependence. It was expected that there would be heterogeneity among individual trial patients. In addition, individual trial patients may contribute one or multiple circuits. It was assumed to be a correlation between an individual trial patient contributing multiple circuits and circuit life. The frailty model was used to test event dependence (where the event is a clotted circuit) within the trial patients. Event dependence in this study meant that an occurrence of one event (time to clotting of the circuit) may make further events (additional circuit clotting times) more or less likely. The advantage of this model is that it considers any within-cluster correlation of circuit life. Proportions were compared using a chi-square test.
First analysis was carried out using IMB SPSS statistics for Windows (v2; IBM, Armonk, NY). Second analysis was performed using SAS (Enterprise Guide v5.1; SAS Institute, Cary, NC).
RESULTS
Participants and Recruitment
One hundred patients were randomized between June 2013 and August 2014. Two patients from each group were randomized but did not receive CRRT. The Consolidated Standards of Reporting Trials diagram for patient enrollment is shown in Figure 1 . Overall, 96 patients (49 in the 150 mL/min group and Critical Care Medicine www.ccmjournal.org e1021 47 in the 250 mL/min group) contributed a total of 463 study circuits: 245 in the 150 mL/min group and 218 in the 250 mL/ min group. Median study circuits per patient were four (IQR, 2-6) and totaled 8,206 CRRT treatment hours.
At randomization, patients were similar with respect of age, sex, severity of illness scores (APACHE II, III, SAPS II), admission source, and diagnosis ( Table 1) . There was a 9 kg difference in patient weight between the two groups (p = 0.03); however, BMI was similar for both groups. Prerandomization renal laboratory variables were also similar for both groups.
Primary Outcomes-Circuit Life
The first analysis incorporated 369 defined clotted circuits. The median circuit life for these circuits (n = 369) was similar for both groups (150 mL/min, n = 196 [ were also similar ( Table 2 ). The probability of the first study circuit from each patient failing due to clotting did not differ between BFR groups (150 vs 250 mL/min; hazards ratio [HR], 0.85; log-rank test = 0.46) (Fig. 2) . The second analysis involved evaluation of all circuit terminations (clotted and electively removed) and revealed that a BFR of 250 mL/min was not more likely to cause clotting compared with 150 mL/min (HR, 1 
DISCUSSION
This is the first known prospective study to examine the effect of BFR on circuit duration in both CVVH and CVVHDF. In a cohort of 100 ICU patients requiring CRRT, three key findings have been identified. First, when BFR is increased to 250 mL/ min, it does not increase circuit life during CRRT. Second, the use of an anticoagulation strategy and longer APTTs extends CRRT circuit life. Third, patients with higher platelet counts were more prone to premature circuit clotting in this study.
Relationship to Previous Studies
The maintenance of circuit patency by prevention of clotting is the greatest challenge associated with providing CRRT for critically ill patients. As a result, many studies have focused on anticoagulation strategies to extend circuit life (7, (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , whereas many aspects of treatment and prescription setting have not been investigated. One RCT has included BFR in the assessment of circuit clotting in CRRT, indicating that BFRs greater than 125 mL/min did not improve circuit survival (28) . This study was conducted in CVVHD mode which is rarely used in current practice (13, 15, 29, 30 ). Pure diffusive modes of hemofiltration such as CVVHD have been shown to be associated with decreased procoagulatory activity in the dialyser membrane when compared with convective modes (31, 32) and make comparisons to CVVH and CVVHDF problematic. One single center study assessing 1,332 treatments from 355 patients concluded that BFR did indeed affect circuit life (12) . In this retrospective audit, the authors suggest a BFR less than 200 mL/min significantly decreased circuit life compared with rates greater than 200 mL/min. They also determined that BFR greater than 300 mL/min led to lower median circuit lives and recommended an optimal BFR of between 250 and 300 mL/min.
Implications of Study Findings
Our data provide evidence to suggest that a faster BFR does not influence circuit life and prescription of rates greater than 150 mL/min makes no difference to the likelihood of clotting in either CVVH or CVVHDF. It has previously been suggested that blood flow should be maintained at 200 mL/min (33-35) and always be greater than 100 mL/min to avoid premature clotting (36) . The ability to maintain consistent and constant flow may be more critical, with the flow and resistance balance being more important. We have previously reported these mechanical factors and their adverse effects on circuit life (10, 37, 38) . Despite many authors suggesting BFRs for CRRT of 200-250 mL/min (12, (33) (34) (35) and international surveys indicating practical prescriptions of greater than 200 mL/min, there has been no endorsements for this setting. The Acute Dialysis Quality Initiative consensus guidelines for operational characteristics from 2002 indicate that blood flow may be increased to augment solute clearance but do not include a recommendation for this prescription (39) . The more recent Kidney Disease Improving Global Outcomes consensus guidelines outline settings for different RRT modalities indicating 150-250 mL/min is typically prescribed for CRRT modes such as CVVH and CVVHDF but makes no recommendations for practice based on evidence (40) .
The use of anticoagulants to prevent extracorporeal clotting and extend circuit life in CRRT has been used for decades (41) . UFH remains the most commonly prescribed anticoagulant (13, 42) worldwide and remains the standard against which other anticoagulant regimens are compared (7, 21, 22, 24, 25, 43) . A regional heparin technique favors patient safety, and anticoagulant free CRRT is used for a high risk of bleeding (44, 45) .
We have previously reported on circuit life in CVVH when no anticoagulation was used compared with low-dose UFH and a regional heparin technique (45) . This study of 300 filters described similar circuit lives for all three methods and has similarities to our findings which indicate the strong association between higher platelet counts and premature circuit clotting.
Strengths and Limitations
This RCT of 100 patients presents for the first time the outcomes of an investigation into the effect of BFR on circuit life in two commonly used modes of CRRT. This analysis is based on a large number of circuits and for 8,206 hours of treatment time. This number of patients and treatment time is representative of a tertiary level ICU and signifies important findings for current CRRT practice. The presentation of our analysis for first circuit (clotted) and the analysis of all circuits using repeated events survival analysis should be the new standard for studies reporting circuit life in CRRT where previously an all circuits analysis may have drawn conclusions not valid due to repeated measures effect. The study was not powered to detect a difference as there was insufficient historical data available to make the appropriate group size calculation. One further limitation may be the defined BFRs used in this study. BFRs less than 150 mL/min or greater than 250 mL/min may have yielded a different outcome. Circuit life (hours) in both groups may be shorter due to the large proportion of patients enrolled have a diagnosis of liver failure and liver transplantation making comparisons to other ICUs difficult. Two membrane compositions were used and anticoagulation according to an established local policy. These two factors may have some influence on our findings.
CONCLUSIONS
A BFR of 250 mL/min does not improve CRRT circuit life compared with a BFR of 150 mL/min. Independent factors that may extend circuit life include anticoagulation strategies, higher APTT, and lower platelet counts.
